The Health Service Executive has said that it will resume administering the AstraZeneca Covid-19 vaccine in modest amounts in acute hospital settings today.
The use of the vaccine had been paused for six days pending an investigation by the European Medicines Agency after a report of very rare blood clotting events in Norway.
The EMA concluded that the vaccine is safe and effective and is not associated with an overall increase in blood clots. The HSE will now provide updated patient information about what to be aware of in relation to these very rare blood clotting events for people offered the AstraZeneca vaccine.